Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Active not recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 1

Conditions

Lymphoma 10Leukemia, Myeloid, Acute 9Hodgkin Disease 8Lymphoma, Non-Hodgkin 7Precursor Cell Lymphoblastic Leukemia-Lymphoma 6Leukemia 6Multiple Myeloma 5Lymphoma, Large B-Cell, Diffuse 5Small Cell Lung Carcinoma 4Sarcoma 4Recurrence 4Neuroblastoma 4Central Nervous System Neoplasms 4Lymphoma, T-Cell 3Lymphoma, B-Cell 3Carcinoma, Non-Small-Cell Lung 3Burkitt Lymphoma 3Teratoma 2Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 2Osteosarcoma 2Optic Nerve Glioma 2Oligodendroglioma 2Neoplasms 2Myelodysplastic Syndromes 2Lymphoma, Large-Cell, Anaplastic 2Lymphoma, B-Cell, Marginal Zone 2Leukemia, Lymphocytic, Chronic, B-Cell 2Immunoblastic Lymphadenopathy 2Congenital Abnormalities 2Breast Neoplasms 2

Interventions

Vincristine 4Prednisone 4Etoposide 4Doxorubicin 4Cyclophosphamide 4Rituximab 3Filgrastim 2prednylidene 1pegylated granulocyte colony-stimulating factor 1pegfilgrastim 1liposomal doxorubicin 1ibrutinib 1etoposide phosphate 1deltacortene 1Ultrasonography 1Procarbazine 1Lomustine 1Lenalidomide 1Granulocyte Colony-Stimulating Factor 1Endoscopy 1Electrocardiography 1Echocardiography 1CT-P10 1Bronchoscopy 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Has results × Lymphoma, AIDS-Related × etoposide phosphate × Clear all
NCT02911142 2025-07-28

Lenalidomide Combined With Modified DA-EPOCH and Rituximab (EPOCH-R2) in Primary Effusion Lymphoma or KSHV-associated Large Cell Lymphoma

National Institutes of Health Clinical Center (CC)

Phase 1/2 Active not recruiting
17 enrolled 21 charts
Lymphoid

Lymphoma, B-Cell, Lymphoma, AIDS-Related, Lymphoma, Primary Effusion

Data powered by HemOnc (CC BY 4.0) Colophon âš¡